Adma Biologics, Inc.
ADMA Biologics Reports Third Quarter 2026 Financial Results and Provides Business Update
3Q 2026 Total Revenue of $141.1 Million, Increasing 5% Year-over-Year
Company newsroom
NASDAQ:ADMA
1 releases
3Q 2026 Total Revenue of $141.1 Million, Increasing 5% Year-over-Year